Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Radiodermatitis × Radiotherapy × Breast × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 201 Triple Negative Breast Neoplasms 14 Breast Neoplasms, Male 14 Carcinoma, Intraductal, Noninfiltrating 13 Inflammatory Breast Neoplasms 12 Lung Neoplasms 11 Prostatic Neoplasms 10 Neoplasms 9 Neoplasm Metastasis 9 Brain Neoplasms 9 Breast Carcinoma In Situ 8 Carcinoma, Ductal, Breast 7 Melanoma 6 Carcinoma, Non-Small-Cell Lung 6 Recurrence 5 Radiation Injuries 4 Lymphoma, Non-Hodgkin 4 Lymphoma, Mantle-Cell 4 Lymphoma, Large-Cell, Immunoblastic 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4 Lymphoma, B-Cell, Marginal Zone 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Hodgkin Disease 4 Dendritic Cell Sarcoma, Interdigitating 4 Carcinoma, Renal Cell 4 Carcinoma, Lobular 4 Burkitt Lymphoma 4 Testicular Neoplasms 3 Small Cell Lung Carcinoma 3

Interventions

Low-Level Light Therapy 5 Petrolatum 2 dimethicone 1 Triamcinolone Acetonide 1 Thioctic Acid 1 Standard of Care 1 Silver Sulfadiazine 1 Radiotherapy, Conformal 1 Radiotherapy 1 Practice Guidelines as Topic 1 Melatonin 1 Laser Therapy 1 Hydrogel, Polyethylene Glycol Dimethacrylate 1 Hydrocortisone 1 Dimethyl Sulfoxide 1 Curcumin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07192588 2025-09-25

GuARD

Graegis Pharmaceuticals Ltd

Phase 2 Active not recruiting

Breast Neoplasms, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡